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The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has
dramatically changed the natural approach of HIV-related cancers. Several studies have
shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients
with cancer, and that the outcome is similar to that of HIV-negative patients receiving
the same AC regimens. However, the concomitant use of HAART and AC can result
in drug accumulation or possible toxicity with consequent decreased efficacy of one or
both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450
and drug–drug interactions (DDIs) with HAART are common. Therefore, it is important
that HIV patients with cancer in HAART receiving AC treatment at the same time receive
an individualized cancer management plan based on their liver and renal functions, their
level of bone marrow suppression, their mitochondrial dysfunction, and their genotype
profile. The rationale of this review is to summarize the existing data on the impact of
HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between
antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy
and minimize the risk of drug–drug interaction, a useful list of pharmacogenomic markers
is provided.
Keywords: pharmacogenomics, polymorphisms cytochrome P450, HIV, AIDS, antiretroviral therapy, cancer,
antiblastic chemotherapy
INTRODUCTION
The assessment of Highly Active Antiretroviral Therapy (HAART) into the clinical setting
had a striking impact on the clinical outcome of HIV-related cancers. The range of cancers
diagnosed among patients infected by HIV/AIDS includes AIDS-defining diseases (ADC—Kaposi’s
sarcoma and non-Hodgkin’s lymphoma) and non-AIDS-defining cancers (NADC—Hodgkin’s
disease, invasive anal carcinoma, lung carcinoma, skin cancer, colorectal cancer, and hepatocellular
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carcinoma). In fact, after the introduction of HAART, a decrease
in ADCs and an increase in NADCs were observed due to
the aging of HIV-positive cancer patients (Antoniou and Tseng,
2005). The challenge in the treatment of HIV-related diseases
is the need to maintain an adequate management of HIV
infection during the antiblastic chemotherapy (AC; Vaccher et al.,
2001). AC induces a significant decrease in the number of CD4
lymphocytes and significantly increases the risk of opportunistic
infections (OIs) in patients with HIV-related malignancies.
Patients who receive a combination of AC and HAART can
achieve better response and survival rates than patients who
receive AC alone. The combined treatment is feasible and reduces
the incidence of OI complications. However, careful attention
must be paid to cross toxicity and possible pharmacokinetic and
pharmacodynamic interactions between antiretrovirals and AC.
Drug–drug interactions (DDIs) occur when one drug influences
the level or activity of another when concurrently administered.
They may result in increased therapeutic or adverse events,
decreased therapeutic or toxicity or a single response that does
not occur when either agent is administered alone (Mounier et al.,
2009)
DDIs could be arise at all levels and a failure to identify them
can result in overdosing or under-dosing the patient. DDIs are
a primary concern in treatment and are more prevalent in the
field of oncology. This could be due to the narrow therapeutic
index and the inherent toxicity of AC. The risk of DDIs
has been found to increase with the number of simultaneous
medications. Cancer patients receive many drugs during their
therapies including those for comorbidity and cancer-related
symptoms such as pain, depression, and emesis. Therefore, they
are at augmented risk to develop DDIs. According to Corona
and colleagues, DDIs are frequent in oncology (Corona et al.,
2008). In most cases, the consequences of DDIs are unwanted,
compromising the effectiveness of the therapeutic agents or
enhancing their toxicity. It has been reported that about 20–30%
of all adverse drug events are caused by interactions between
medications. To date few partial data are available on DDIs in the
treatment of HIV-associated cancers. Protease inhibitors (PIs)
and non-nucleoside reverse transcriptase inhibitors (NNRTIs)
are potent inhibitors/inducers of the cytochrome P450 (CYP450)
metabolic system. Since many AC are also metabolized by the
CYP450 system, co-administration with HAART could result in
drug piling up and possible adverse event or decrease the efficacy
of one or both type of drugs (Dubrow et al., 2012).
In this field, the inter-individual response could be dependent
on genetic variability in the population (Di Francia et al., 2015a).
A few examples showing the correlation between toxicities and
single nucleotide polymorphisms (SNPs) in the genes coding for
metabolizing enzymes and drug-transporters are described here.
Amplified toxicity may lead to a delay of chemotherapy
recycling or to a prompt dose reduction, possibly compromising
the therapeutic benefit of AC (Flepisi et al., 2014). Toxicity can
also negatively affect antiretroviral therapy compliance, favoring
the emergence of resistant HIV strains. Recent data have shown
that toxicity, particularly myelosuppression, and neurotoxicity, is
significantly more common in patients treated with combined
therapy than in patients treated with antineoplastic drugs
alone (Harrys and Mulanovich, 2014). Alternatively, patients
treated with chemotherapy plus HAART have a better survival
rate than patients treated with chemotherapy alone, suggesting
that the reduction of OI morbidity caused by HAART with
the consequent amelioration of their performance status, can
improve the overall outcome in the combined treatment
setting (Beumer et al., 2014). This paper reviews the potential
interactions and subsequent therapeutic considerations in the
combination of HAART and AC used in the treatment of
HIV-positive cancer patients.
HAART CLASSIFICATION AND DRUG
METABOLISM
In general, guidelines for naive HIV patients recommend the
combination of three active drugs in order to prevent the
occurrence of resistance: a combination of two nucleoside
reverse transcriptase inhibitors (NRTIs) with either an NNRTI,
or a PI boosted with ritonavir, or an integrase strand transfer
inhibitor (INSTI). US Department of Health and Human
Services (DHHS) guidelines recommend HAART for all HIV-1
patients with a CD4 T cell count <500 cells/µL, in order
to preserve immune function while declining HIV-associated
comorbidity and mortality. Similar regimens can be used in
HIV-positive cancer patients according to the treatment plan
(AC or radiotherapy or surgery), the presence of liver or renal
diseases, bone marrow suppression, mitochondrial dysfunction,
and patient preference (Harrys and Mulanovich, 2014). For the
majority of antiretroviral drugs that are CYP 450 substrates,
inducers or inhibitors, co-administration with other CYP 450
metabolized drugs can result in drug accumulation and potential
toxicity or decreased efficacy of one or multidrugs (Rudek
et al., 2011; Beumer et al., 2014). Particularly, inhibitor drugs
for CYP450 enzymes typically cause reduced metabolism of
other drugs that are substrate of the same enzyme (Table 1).
This decreased metabolism may result in higher plasma drug
levels and increased toxicity. Inhibition of CYP450 is rapid,
with the maximal inhibitory effect going up when steady-state
concentrations of the inhibitor are recognized. Equally, induction
of the CYP450 system results in the augmented clearance of drugs
concurrently metabolized by the same enzyme and a decrease of
the drug concentration. Enzyme induction occursmore gradually
than inhibition because the complete effect of the drug depends
on the time necessary for new enzyme creation and the half-life
of the inducing molecules (Mounier et al., 2009).
Nucleoside Reverse Transcriptase
Inhibitors (NRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs), sometimes
called “nucleoside analogs” or “nukes,” contain faulty versions of
the building blocks (nucleotides) used by reverse transcriptase
(RT). The RT enzyme has two enzymatic functions. Firstly, it
acts as a where it transcribes the single-stranded into single-
stranded DNA and subsequently it builds a complementary
strand of DNA. This provides a DNA double helix which can
be integrated into the host cell’s chromosomes. Secondly, it has
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ribonuclease activity as it degrades the RNA strand of the RNA–
DNA intermediate that is formed during viral de novo DNA
synthesis. RT incorporates the faulty NRTI building blocks and
de novo DNA cannot be correctly synthesized. As a result, HIV’s
genes can’t be incorporated into the healthy de novo DNA and
the cell cannot produce new viruses. For NRTIs, probability
for DDIs is minimal because these agents are not eliminated
by the CYP 450 system and do not induce or inhibit CYP
450 enzymes. However, NRTIs may be victims of transporter-
mediated interactions because renal clearance is their primary
route of elimination. NRTI-based treatments are associated
with anemia, dyslipidemia, diarrhea, emesis, insulin resistance,
neutropenia, nephrotoxicity, lactic acidosis, hepatosteatosis, and
an improved risk of cardiovascular adverse effects (Harrys and
Mulanovich, 2014). Tenofovir may lead to renal dysfunction
principally in patients getting nephrotoxic drugs. Renal function
must be monitored over time, and the dose adjusted in the
case of nephropathies. Patients under treatment with abacavir
(ABC)-lamivudine in predetermined dose combination, genetic
screening for HLA-B∗ 57.01 should be performed to prevent
the risk of a hypersensitivity reaction to ABC (Beumer et al.,
2014). Susceptibility to this reaction appears to be genetic and
has been associated with HLA-DR7 haplotypes. Recent data has
shown a susceptibility locus within the B∗57.01 haplotype that
was present in 94% of patients with ABC hypersensitivity (Rudek
et al., 2011).
Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs),
despite their chemical diversity, bind all at the equivalent site
in the RT. The binding occurs allosterically in a hydrophobic
pocket located around 10 Å from the catalytic site of the
p66 subunit of the enzyme. The NNRTI binding site (NNIBP)
contains five aromatic, six hydrophobic, and five hydrophilic
amino acids that belong to the p66 subunit and additional two
amino acids (Ile-135 and Glu-138) belonging to the p51 subunit.
Every NNRTI interacts with different aminoacid residues in the
NNIBP, and all are extensively metabolized via the CYP450
enzyme system (Mounier et al., 2009). The probability for DDIs
is elevated because these agents are widely metabolized by or
inhibit the CYP450 system (Harrys and Mulanovich, 2014).
These regimens are associated with rash, central nervous system
toxicity, and high hepatic transaminase levels. Central Nervous
System (CNS) side effects have been noted in up to 52% of
patients but are sufficiently severe to require discontinuation in
only 2 to 5%. There is a potential toxic additive effect with alcohol
or other psychoactive drugs. Nevirapine acts as an inducer of
CYP3A4 and Efavirenz can either inhibit or induce CYP3A4
activity. Efavirenz most often acts as a CYP3A4 inducer and
may also induce CYP2B6 (Tsuchiya et al., 2004). Etravirine, a
second generation NNRTI, is a weak inducer of CYP3A and
a weak inhibitor of P-glycoprotein and constitutes a valuable
option for concomitant use with BEACOPP chemotherapy
for advanced HD (Kurz et al., 2015). Rilpivirine is primarily
metabolized by CYP3A but does not induce the P450 system
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and theoretically should not affect immunosuppressant drug
levels (Tsuchiya et al., 2004).
Protease Inhibitors (PIs)
Protease Inhibitors (PIs), prevent viral replication by selectively
binding to HIV-1 protease and blocking the production of
infectious viral elements. The HIV protease contains a binding
pocket into which drugs should fit to inhibit the activity of
the enzyme. As HIV duplicates, constant mutations change the
profile of this configuration. Drug resistance occurs when some
of these mutations inhibit the binding of one or more PIs. The
early resistancemutations that are selected can differ between PIs,
but are all located near the substrate-binding gap of the enzyme.
These primary mutations lead to simultaneous resistance to
multiple PIs. During PI therapy, additional mutations (secondary
mutations) should be identified in the protease that leads to
high-level PI resistance. As a result, cross-resistance is one of
the most important problems related with PI treatment (Shafer,
2006). Ritonavir (RTV) is one of the most powerful CYP3A4
inhibitor. Also, it is an active inhibitor of ABCB1, CYP2C8,
CYP2D6 and a weak inducer of ABCB1, CYP2B6, CYP2C9,
CYP3A4 (Kiser et al., 2008). Second-generation of PIs (i.e.,
atazanavir, darunavir, fosamprenavir, lopinavir, and tipranavir)
are active against HIV acquired mutations because therapy
with the older PIs. Darunavir and tipranavir are different from
the others PIs in that they are synthetic non-peptide drugs.
PI regimens are related with dyslipidemia, fat misdistribution,
insulin resistance, hepatic transaminase elevation, and an
increased risk of gastrointestinal and cardiovascular events.
Hepatotoxicity is more frequent and more severe with full dose
RTV than with other PIs. This toxicity is reduced with the lower
RTV doses used in dual-PI combination. QT prolongation has
been linked in particular with PIs such as atazanavir, saquinavir,
and ritonavir-boosted lopinavir (Rudek et al., 2011)
Integrase Strand Transfer Inhibitors
(INSTIs)
Integrase strand transfer inhibitors (INSTIs) are a class of
antiretroviral drug aimed at blocking the action of integrase.
Integrase are specialized viral enzyme able to inserts the viral
genome into the DNA of the host cell. Since integration
is a vital step in retroviral replication, blocking it can halt
further spread of the virus. Since integrase inhibitors target
a different step in the retroviral life cycle, they may be
taken in combination with other types of HIV drugs to
minimize adaptation by the virus. They are also useful in
salvage therapy for patients whose virus has mutated and
acquired resistance to other drugs. Raltegravir, the first approved
INSTI, is metabolized only by UDP glucuronosyltransferase
1A1 (UGTA1A1) and is unlikely to have major interactions.
Raltegravir is neither an inhibitor nor an inducer of CYP1A2,
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
Also, it doesn’t interfere with P-glycoprotein-mediated drug
transportation. Therefore, it can be a suitable alternative for the
prevention of AC–HAART interactions (Tsuchiya et al., 2004).
It has been associated with abnormal creatine kinase plasma
levels, rhabdomyolysis, and myopathy. Elvitegraviris is primarily
metabolized by CYP3A4/5 and partly by glucuronidation via
UGT1A1/3 and is a component of an FDA-approved fixed-dose
combination tablet (Stribild) containing tenofovir alafenamide,
emtricitabine, and the CYP3A4 inhibitor cobicistat. Dolutegravir
has a minor role with CYP3A4 because it is metabolized by
uridine 5-diphosphate-glucuronosyltransferase. Common side
effects are insomnia, allergies, headache, and anomalous liver
function in patients who have concurrent hepatitis B or C. Also,
it causes augment of the serum creatinine level due to inhibition
of tubular secretion of creatinine (Ritchie et al., 2006)
CCR5 Receptor Antagonists
CCR5 receptor antagonists are a group of small molecules that
blocking the CCR5 receptor. The C-C pattern chemokine
receptors CCR5 and CXCR4 are the most important
chemokine receptors implicated in the HIV entrance
method. These receptors fit in to the seven transmembrane
G-protein-coupled receptor’ (GPCR) family and are mainly
expressed on macrophages, T-cells, dendritic cells, and
Langerhans cells. They cooperate as co-receptors that HIV-1 uses
to bind cells before viral fusion and entry. HIV isolates could
be divided into R5 and X4 strains, depending to the co-receptor
used (respectively, CCR5 or CXCR4). The CCR5 antagonist
maraviroc is a substrate of ABCB1 CYP3A but does not alter
transport and/or metabolism. Also it is not likely to make DDIs.
It has been related with upper respiratory tract infections, fever,
rash, and hepatotoxicity (Ritchie et al., 2006).
Fusion Inhibitors
Fusion inhibitors are a class of molecules designed to disrupts the
HIV-1 fusion protein equipment at the final stage of fusion with
the hosting cell, and prevent non-infected cells from becoming
infected. HIV binds to the host CD4+ cell receptor via the viral
protein gp120; gp41, a viral transmembrane protein, and then
undergoes a conformational change that assists in the fusion of
the viral membrane with the host cell membrane. Enfuvirtide
binds to gp41 preventing the formation of an entry pore for the
capsid of the virus, keeping it out of the cell. Enfuvirtide is not
metabolized by CYP450 but undergoes hydrolysis and to date
no drug interaction have been noted with this agent. Side effects
associated with enfuvirtide include diarrhea, fatig, nausea, and
injection site reactions (Beumer et al., 2014).
ROLE OF PHARMACOGENOMICS
ASSOCIATED WITH HAART
Even though the benefits of HAART, wide individual variability
has been reported in reply to treatment and in the adverse effects
of certain antiretroviral drugs. Indeed, response to HAART
is extremely complex and often limited by the development
of short- or long-term toxicities and the coming out of
antiretroviral drug resistance. This unpredictability could be
explained by factors that normalize the bio-availability of
drugs (pharmacokinetics), special effects on the host (host
pharmacodynamics), and the activity of the virus itself (viral
pharmacodynamics).
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It is clear that the efficacy of therapy depending by viral
sensitivity to therapy. Mutagenesis in the viral genome is a
physiological process. In fact, mutations should happen in
each duplication cycle, so enabling the virus to adapt rapidly.
Furthermore, initial antiretroviral therapy can be compromised
by transmitted HIV drug resistance. A list of the primary viral
resistance against HAART is available in Shafer (2006).
In addition to viral mutations, further factors may also
provide to treatment failure, likely inter-individual variability
in the pharmacokinetics of antiretroviral drugs. This may be
direct, because sub-therapeutic drug concentration can augment
the hazard of a low virologic response, or indirect, when
high (toxic) drug levels lead notable intolerability, showing
to poor adherence to the treatment. These (THIS) variability
among patients is probably driven by genetic and environmental
factors such as DDIs, body weight, drug–food interactions,
and sex. In particular, DDIs and genetic polymorphisms in
drug-metabolizing enzymes and drug transporters add to
extensive variability in drug pharmacokinetics and toxicity. A few
examples are reported in Table 1.
The CYP2B6 gene is extremely polymorphic, and more than
28 alleles have been characterized (about 100 SNPs). Among
different variants, the CYP2B6∗6 haplotype (516 G>T, and
785A>G) leads to reduced catalytic activity and a significant
decrease in protein expression. Several studies have reported
correlations of Nevirapine and Efavirenz to neurotoxicity with
CYP2B6∗6 (516G>T) homozygous individuals (Haas et al.,
2005).
Several polymorphisms of the CYP2C19 gene are associated
with reduced enzyme activity. In particular, theCYP2C19∗2 allele
leads to a 681G>A substitution, causing a stop codon splicing
variant. These poor metabolizing patients have a favorable
response (in term of viral suppression) to exposure to Nelfinavir
(Haas et al., 2005).
Unpredictability in metabolic CYP3A5 function is mainly
accredited to the CYP3A5∗3 polymorphic allele and, to a
smaller extent, to the CYP3A5∗6 and CYP3A5∗7 variants. The
variant CYP3A5∗3 allele produces an alternative mRNA splicing,
resulting in trunked protein due to the formation of a untimely
stop codon (Anderson et al., 2009). Haplotype CYP3A5∗3
has been related with significantly reduced clearance of both
indinavir and saquinavir (Anderson et al., 2006).
The CCR5 antagonist maraviroc is a substrate of ABCB1 and
CYP3A but does not alter drug transport or metabolism and is
not likely to stimulate enzyme-mediated interactions. It has been
associated with hepatotoxicity, and infections among individuals
with CCR5-Delta32 mutations (Wheeler et al., 2007).
Association of polymorphisms in ATP-binding Cassette
(ABCC) with efficacy of therapy was also found as drug
transporters are seen as one of the primary mechanisms related
to sub-therapeutic antiretroviral drugs concentrations of. Major
studies shown a relationship between the ABCB1 polymorphism
(3435 C>T) and hepatotoxicity risk after nevirapine treatment.
This genotype-phenotype association was established by Ritchie
et al. (2006), who described that the ABCB1 3435 TT allele was
fewer frequent in the patient group recording hepatic toxicity
than polymorphic 3435CC. Nevertheless, a pharmacogenetic
study that integrated the C421A and G34A variants, that were
linked in vitro with a decrease in ABCG2 activity, found no
relationship of these polymorphisms with cellular accumulations
of zidovudine and lamivudine triphosphate. Few studies are
available on other Nucleosides analogs (Kohlrausch et al., 2010).
Recent data propose an important role for influx via the
Solute Carrier Organic Transporters (SLCO alias OATP) family
in the pharmacokinetics of antiretroviral agents. In detail, it has
been observed that the SLCO1B1 521T>C polymorphism was
significantly related to higher plasma concentrations of lopinavir
in patients homozygous for the mutant allele (521CC), which
would suggest that the entry of lopinavir into the liver via the
SLCO1A2 influx transporter is an important determinant of
exposure to lopinavir (Kohlrausch et al., 2010).
Recent studies in patients who received atazanavir and
indinavir established that the proportion of grade 3–4
hyperbilirubinemia was 80% among patients homozygous
for the UGT1A1∗28 allele, 29% in heterozygous patients and
18% in patients homozygous for the wild-type allele, respectively
(Rodríguez-No’voa, S. et al, 2007).
Even if there is clinical usefulness of the described
polymorphisms implicated in HAART based-therapy, whether
pharmacogenetics testing improves clinical outcomes is still
an open query. In fact, the cost-effectiveness of the genotyping
is still unknown and clinical expertise in the interpretation of
laboratory results is urgently needed (Di Francia et al., 2012,
2014).
ASSESSING HEPATIC FUNCTION IN
PATIENTS ON HAART
Bilirubin values is frequently used as a guide for dosage
adjustment in AC. Several antiretrovirals such as atazanavir
or indinavir are related with unconjugated hyperbilirubinemia
resulting to UGT1A1 inhibition similarly to that occurring
in Gilbert’s syndrome. Unconjugated hyperbilirubinemia in
combination with HAART and in the absence of other
evidence of hepatic dysfunction could be unnoticed in AC
dosing. Conversely, NRTIs such as didanosine, stavudine, and
zidovudine can produce steatosis and lactic acidosis. These
antiretrovirals should be blocked or replaced prior to initiating
AC agents that undergo hepatic metabolism. In fact, NRTIs such
as abacavir, emtricitabine, lamivudine, and tenofovir or NNRTIs
such as efavirenz are fewer probable to be hepatotoxic and could
be used in place of the others (Rudek et al., 2011). In addition,
several cases have been associated to primary hepatocellular
carcinoma in HIV-positive patients (Nunnari et al., 2012).
ANTICANCER TREATMENT OVERVIEW
The therapeutic strategy should take into consideration three
essential elements: (i) the histological nature of the neoplasm;
(ii) the estimation of the extension of the tumor disease; (iii)
the evaluation of the general state of disease. Surgery and/or
radiation therapy provide local control of the tumor while AC is
dedicated to the prevention or treatment of metastatic disease.
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In recent years, monoclonal antibodies have achieved a great
clinical diffusion and therefore, the importance of both the
identification of tumor targets and the characterization of the
resistance mechanisms is increasing (Shafer, 2006).
Kaposi’s Sarcoma (KS)
In the HAART era, KS remains the second most frequent
tumor in HIV-infected patients worldwide (Martellotta et al.,
2009). Treatment decisions have to take into consideration
the extent and the rate of tumor growth, the patient’s
symptoms, immune system conditions, concurrent HIV-related
complications, and Epstein–Barr virus (EBV) co-infection
(Pinzone et al., 2015). Local therapy (intralesional vinblastine,
oral etoposide, cryotherapy, and excisional surgery) is reserved
for patients with minimum skin disease as cosmetics, and
as palliative treatment for non-responders to systemic AC
who have speedily progressive disease (PD; Simonelli et al.,
2009). Radiotherapy is efficacy and usually represents the best
topic therapeutic approach for treatment of pain, edema, and
bleeding. HAART including PI, alone or in combination with
local therapy, represent the first-line treatment for stage T0
and T1 slowly PD. HAART with concomitant AC is eligible
for visceral disease and/or rapidly progressive disease, and
maintenance (M)-HAART after AC can be useful as anti-
KS treatment after AC (91% overall response rate). Systemic
AC is reserved for non-responders patients to HAART and/or
have widespread, symptomatic, rapidly PD, life-threatening
disease with visceral involvement and an IRIS-associated flare.
Liposomal anthracyclines (doxorubicin 20mg/m2 i.v. every 2
weeks or daunorubicin citrate liposome 40mg/m2 i.v. every 2
weeks) are now considered as the first-line therapy for patients
with advanced AIDS-KS. Intravenous paclitaxel (100mg/m2
given every 2 weeks as a 3-h infusion) or intravenous Irinotecan
(150mg/m2 day 1; 10 every 21 days) plus HAART including PI
is reserved for patients with persistent or recurrent AIDS-related
KS after than first-line AC (Corona et al., 2008).
Non-Hodgkin’s Lymphoma (NHL)
From the time when the beginning of the AIDS epidemic
NHL has been related with HIV infections. About 80–90%
of HIV-associated NHLs are classified as intermediate or high
grade NHL, and almost all are of B lymphocyte origin. The
development of HIV-associated NHL has been shown to be
connected to older age (>35 years), low CD4 cell count
(<100/mm3), high serum LDH, and no previous treatment with
HAART. In addition, these factors jointly with low performance
status (>2) and the involvement of more than two extra nodal
sites are related with poor clinical outcome and shorter survival
in HIV-NHL. It is also contemplation that immune stimulation
by HIV and reactivation of prior EBV infection owing to
imperfect T-cell surveillance leads to long-term stimulation and
proliferation of B-lymphocytes, resulting in the development of
HIV-NHL (7). Since the extensive use of HAART, the prognosis
of HIV-NHL has improved, with a better tolerance to AC, a
higher complete remission (CR) rate, a significant improvement
in disease-free survival (DFS) and an important reduction in
the number of deaths related to HIV complications. Many
studies have shown that the R-CHOP regimen (rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone)
can be considered as the conventional approach for patients
with CD20-positive diffuse large B-cell NHL in the HIV setting
(Vaccher et al., 2001). With respect to the make use of rituximab,
it is significant to point out contradictory results. Recent results
have emphasized reservations on the safety of the R-CHOP
combination therapy in patients with HIV (Beumer et al., 2014).
Hodgkin’s Lymphoma (HD)
It is described that HIV-infection increases the risk of developing
HD about 8- to 10-fold compared with the healthy population
(Rios, 2014). HIV-HD is characterized by numerous critical
features such as elevated frequency of advanced stage disease
(i.e., mixed cellularity or lymphocyte depleted histological
subtypes), and extra nodal involvement. An optimal therapy for
HIV-HD has not been defined (Rios, 2014). Since patients have
advanced HD, they have been treated with polichemotherapy
i.e., MOPP (mechlorethamine, vincristine, procarbazine, and
prednisone), or currently with ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine), but the CR rate remains lower
than that of “primary” HD. The main problem in therapy is
immunosuppression caused by AC that can further synergize
the immunocellular deficit of HIV-infected patients, and can
facilitate the beginning of OIs and/or the evolution of the
HIV infection itself. Also, even though CD4+ cell counts in
these patients are typically normal or a little decreased at
diagnosis, they may become strictly reduced during and after
AC, leading to a higher susceptibility to OIs. In conclusion,
leucopoenia, usually present in patients with HIV-HD due to
previous therapy with nucleoside analogs and/or HIV-related
myelodysplasia, sporadically makes conventional doses of AC
difficult to administer. For the disseminated disease, early
experience suggests that antiretrovirals can be used concurrently
even with dose-intense regimens including the BEACOPP
regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone; Cherif et al., 2015).
Squamous Cell Carcinoma of the Anus
(SCCA)
The gastrointestinal (GI) tract is one of the most widespread
sites of opportunistic infections in HIV-infected patients. SCCA
is a relatively uncommon cancer of the GI tract, constituting
only 1.5% of all digestive system cancers. Recent data describe
not only a different SCCA incidence rate among HIV-positive
and HIV-negative patients but also increased incidence rates
of SCCA among HIV-infected patients in the HAART era
compared to the pre-HAART era. The risk of SCCA is 120-fold
greater in HIV-positive than in HIV-negative patients and in
the setting of HIV it appears to be higher for patients with
lower CD4+ T-cell counts. In addition to the augmented
risk of developing SCCA, HIV-infected individuals may have
higher SCCA-related morbidity and mortality (Martellotta et al.,
2012). In fact, the 5-year survival ranges from 47 to 60%,
which is lower than the 73% 5-year DFS rate reported in the
common population. In relationship with HAART, a hard line
approach to the treatment of SCCA in HIV-infected patients
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is necessary, as reported for other NADCs (Spina and Tirelli,
2004; Shafer, 2006). In fact, patients who receive the AC plus
HAART combination can get the best response rates and the
highest survival rates than those who receive AC alone. Surgery
has been reserved for salvage therapy for non-responders or
recurrent disease. A role for surgery also remains for selected
patients with small, superficial tumors of the anal margin and
those with lesions <2 cm that seldom have nodal involvement,
and that can be advantaged by local excision. Several series
and prospective trials have demonstrated the feasibility and
efficacy of combined therapy consisting of radiotherapy (RT)
and concurrent AC. This typically includes 5-fluorouracil (5 FU)
and mitomycin C (MMC). Two European phase III randomized
clinical trials evaluated the benefits of combined therapy vs. RT
alone. Both trials demonstrated a significant increase in CR rates,
an improvement in local control, and a significant decrease in
local failure and need for colostomy in the combined therapy
arm vs. the RT alone arm. For the combined therapy arm,
a 5-year survival rate of 56% and 3-year survival rate of 65% were
reported, respectively. An American phase III trial examined the
importance of MMC in the standard combined therapy regimen
and demonstrated a significant reduced local failure rate, and
improved colostomy-free and DFS rate with the addition of
MMC compared to 5-FU alone-based CMT (Zanet et al., 2011).
Lung Cancer
The increased incidence of lung cancer during the HAART era
may be related to prolonged life expectancy of HIV-positive
patients, the longer period of immune suppression of these
patients and in particular the increased total number of cigarettes
they smoke. Recent studies show that lung cancer is more
common in association with acceptable immune competence
than in the more advanced stages of HIV infection (Bearz
et al., 2014). Because lung cancer has an impact on the
overall survival (OS) of HIV-positive patients suffering from this
neoplasia, the patients with advanced stage lung cancer should
be treated accordingly to standard regimens used in the general
population (platin-based chemotherapy and/or radiotherapy).
The combination of AC and HAART is feasible and supports
the protective effect of HAART which co-induces a significant
improvement in the OS (Bearz et al., 2012).
Cervical Cancer
Invasive cervical cancer affects the uterine cervix. The mainly
common histological types are squamous cell (69%) and
adenocarcinoma (25%). It may be caused by a persistent Human
Papillomavirus (HPV) infection; in particular HPV 16 and 18
are associated with more than 90% of cervical cancer cases.
It has been known that women HIV patients have a higher
incidence of HPV infection and the HPV–HIV co-infection
is believed to induce both disruption and dysregulation of
the humoral and cellular of local and systemic immunity
with consequent rapid disease evolution. Generally, cervical
intraepithelial neoplasia (CIN) progression forward to invasive
cervical cancer in uninfected women can get some years those
age between 45 and 50 years old. In women HIV patients, CIN
progresses more speedily occurring between 16 and 40 years
old and is usually resistant or responds less well to treatment
(Dubrow et al., 2012).
Colorectal Cancer (CRC)
Colorectal cancer (CRC) is the third principal cause of cancer
death in the general population. Considering that HIV is now a
chronic disease, many patients are living long enough to develop
CRC. However, few studies have evaluated the incidence of
CRC in HIV-positive cohorts and the majority of them have
not considered that the risk of CRC is increased among HIV
infected people. However, a major limitation is the lack of
data regarding rates of CRC screening in the HIV population
due to scarce adherence to screening program. Available data
suggest that HIV-infected patients with CRC present with more
advanced disease and at a younger age than individuals without
HIV infection (Di Benedetto et al., 2013). The GICAT group
has compared the clinical presentation and outcome of 27
HIV-positive patients and 54 age- and sex-matched controls with
CRC, concluding that HIV-positive patients had a lower PS, a
poor Dukes’ stage, a the highest grading and the shortest survival
than uninfected subjects (Berretta et al., 2010). Regarding the
concomitant use of HAART and AC, another study from the
GICAT group has demonstrated that it is feasible, safe and
effective, especially for the Folfox4 treatment in metastatic CRC
HIV-positive patients (Berretta et al., 2008).
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC) is the most common primary
cancer of the liver, and according to the WHO report, the
fourth most common cause of death (Jong-wook, 2003; Bosch
et al., 2004; Gomaa et al., 2008). The risk of HCC is seven-fold
higher in HIV-infected than in HIV-uninfected patients. Since
the introduction of HAART, no decrease in the incidence of HCC
has been observed, unlike other HIV-associated cancers (Clifford
et al., 2008; Berretta et al., 2011).
In the general population, HCC occurs several decades after
the initial infection with HCV or HBV (El-Serag et al., 2008).
Although, it was suspected that HIV infection alone may be a
risk factor for HCC, this theory seems to have been excluded
in huge retrospective cohort studies (Clifford et al., 2008).
Conversely, in HIV-positive patients, co-infection with HCV
or HBV is common and a notably higher risk of developing
HCC through improvements in immune reconstitution due to
chronic viral hepatitis are well-recognized. Still modest is the
knowledge about the relations between HIV and HBV and/or
HCV over the long-term: HIV co-infection seems to increase
disease progression and decrease the efficacy of both anti-HCV
and anti-HBV treatments. Nevertheless, it is ambiguous whether
HIV infection directly increases the probability of HCC in viral
hepatitis patients (Salmon et al., 2006; Berretta et al., 2011).
In addition to the increased risk of rising HCC, patients with
HIV infection may have higher HCC-related co-morbidity and
death. Several studies have shown that HIV/HCV co-infected
individuals with HCC, develop liver cirrhosis more quickly and
more aggressive thanHCV-mono-infected patients. However, the
clinical procedures of HCC in an HIV-infected setting is not yet
well-defined, since most earlier studies have had little sample
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sizes and/or many HIV patients were not undergoing HAART
treatment.
Recently a GICAT Study, in a large retrospective analysis,
demonstrated that in the majority cases of HCC-HIV patients,
was diagnosed in patients with well-controlled HIV infection and
a good PS (Berretta et al., 2011). The age at HCC diagnosis was
younger in HIV-infected than in uninfected patients, and HCV
co-infection was an additional risk factor, with a poorer prognosis
in terms of lower median survival-time, when compared
to HIV-uninfected patients, regardless of HIV-infection fine
control. As predictable, HIV-patients also showed the shortest
mean time of progression from Chronic Liver Disease to HCC.
Moreover, a lot of different significant findings come out from
their results. First, HIV-infected patients that developed HCC
were co-infected with HCV or HBV in the great greater part
of cases. Second, in HIV-infected patients, HCC was diagnosed
more frequently in the early stages (66% in stages A or B)
and was for this reason amenable to curative approaches. In
spite of this result, the median survival of the HIV-infected
cohort was poorer with respect to that of the HIV-uninfected
cohort, where HCC was diagnosed at more advanced stages
(58% were in stages C or D) and was hence more infrequently
amenable to curative approaches. Third, HIV-infected patients
on HAART at HCC diagnosis showed a better prognosis than
patients not on HAART. Fourth, no response rate differences
were found as regards potentially curative treatments both at
diagnosis and at recurrence between two groups, although in the
case of HCC disease progression after treatment, HIV-infected
patients were re-treated significantly less frequently than
HIV-uninfected patients. The authors concluded that in their
study HCC-HIV-positive patients showed a significant higher
median survival (35 months) with respect to data reported
by a previous study (Di Benedetto et al., 2013). Additional
significant data emerging from the GICAT study concerning
the treatment scheduled for HIV-infected patients: in about
one-third of HIV patients, HCC was treated with potentially
curative options. More recently, also from the GICAT group, it
has been demonstrated for the first time that the concomitant
use of Sorafenib and HAART is safe and feasible, without major
complications and/or toxicities reported (Berretta et al., 2013).
In conclusion the concomitant use of HAART, during the most
important treatment for HCC in HIV-positive patients seems
feasible and safe.
DRUG INTERACTIONS CAUSED BY
HAART/AC COMBINATION
The safeguarding of dose schedule and dose-intensity are
the primary goals in treating cancer (Beumer et al., 2014).
Several studies have shown that intensive AC protocols are
practicable in HIV-patients and the outcome of some of these
patients affected with either Burkitt lymphoma or Hodgkin
Lymphoma or diffuse large B-cell lymphoma is similar to
that of HIV-negative patients receiving the same AC regimens
(Ratner et al., 2001). The timing of diagnoses of HIV and
a malignancy must guide therapy decisions. In some cases,
cancer treatment should take priority over HAART despite
the risk related with HIV treatment discontinuation. However,
HAART is always recommended, especially if a patient is
diagnosed with HIV and malignancy, to prevent the emergence
of resistant HIV strains, OI, and death (Beumer et al., 2014;
Harrys and Mulanovich, 2014). Nowadays the availability of
more than 20 approved antiretrovirals and the possibility
of individual genotype profiling, allows the development of
protocols that minimize the potential DDIs and improve
agreement with HAART during AC (Di Francia et al., 2015a,b).
Anthracyclines, antimetabolite agents, antitumor antibiotics, and
platinum undergo non-CYP450 routes of elimination and would
be unlikely to be altered by HAART. Camptothecins undergo
non-enzymatic routes of elimination and are substrates but
not inhibitors or inducers of CYP450 and UGT iso-enzymes
and, therefore, are likely to be altered by HAART (Harrys and
Mulanovich, 2014). Then again, DDIs can be anticipated with
alkylating agents, corticosteroids, epipodophyllotoxins, taxanes,
tyrosin-kinase inhibitors, and vinca alkaloids (Table 2).
Taxanes
Several trials have established the efficacy of paclitaxel for the
treatment of AIDS-related KS. Concomitant administration of
paclitaxel with CYP3A4 inhibitor causes an increase in taxane
concentrations with an increased risk of severe myelosuppression
and peripheral neuropathy (Leandro-García et al., 2012). The
CYP3A4 inducers dexamethasone and efavirenz do not have an
important effect on docetaxel exposure (Rudek et al., 2014). In an
in vivo experiment, docetaxel 20mg/kg IV was administered in
the both concomitant and absence of dexamethasone or efavirenz
for 4 days, or single dose ketoconazole or ritonavir. The CYP3A4
inducers efavirenz and dexamethasone did not have a noteworthy
effect on docetaxel AUC. Nevertheless, the CYP3A4 inhibitors
ritonavir and ketoconazole resulted in a 6.9- and a 3.1-fold
increase in docetaxel AUC, respectively (Rudek et al., 2014).
Vinca Alkaloids (Vinblastine, Vincristine,
Vinorelbine)
The vinca alkaloids remain an important class of AC traditionally
used in the treatment of breast, lung, testicular cancer and
currently (Vinorelbine, Vinblastine) also in the management of
AIDS-related KS. Vinca alkaloids are substrates of CYP3A4 and
are susceptible to PI and NNRTI. Concomitant administration
with CYP3A4 inhibitors antagonizes vinca alkaloids
metabolism with an increased risk of neurotoxicity and severe
myelosuppression. Interaction between ritonavir/lopinavir and
vincristine is mainly responsible for paralytic ileus. In fact,
vincristine is transferred by P-gp and is metabolized by CYP3A4.
Ritonavir is a potent CYP3A4 and P-gp inhibitor. Lopinavir is
also a P-gp inhibitor. These PIs can induce a delayed vincristine
elimination (Kohlrausch et al., 2010). Conversely, CYP3A4
inducers cause decrease of vinca alkaloids concentrations with
decreased efficacy of drugs. In addition, the impact of SNPs
on the drug transporter SLCO1B1 is related to plasma levels of
Lopinavir and Ritonavir (Kohlrausch et al., 2010).
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Epipodophyllotoxins (Etoposide and
Teniposide)
This class of AC is primarily used for the management of
hematological malignancies. Their metabolism is mediated
by the CYP3A4 pathway; therefore, inhibition of the
CYP3A4 pathway can increase blood concentrations of
epipodophyllotoxins with an increased risk of mucositis, liver
toxicity and myelosuppression (Antoniou and Tseng, 2005;
Beumer et al., 2014).
Alkylating Agents (Cyclophosphamide and
Ifosfamide)
Despite their structural similarity and similar mechanisms
of action, significant differences exist in the metabolism of
cyclophosphamide and its isomer ifosfamide. Cyclophosphamide
is an alkylating agent used in the management of HD and
NHL for patients with HIV and is metabolized by two separate
pathways (CYP3A4 and CYP2B6). Induction of CYP2B6 may
increase the amount of active formed metabolite; conversely
PI may decrease the efficacy of cyclophosphamide through
CYP2B6 inhibition. A pharmacokinetic analysis conducted
in 29 HIV-positive patients with NHL treated with CHOP
with and without concomitant indinavir showed a reduce of
cyclophosphamide clearance from 70 to 41–46mL/min/m2. This,
didn’t translate into extreme toxicity (Spina and Tirelli, 2004).
Induction of CYP3A4 could make more drug available for the
4-hydroxylation route and increase the efficacy and toxicity
of cyclophosphamide. In contrast, ifosfamide is administered
as a racemic mixture of its two enantiomeric forms: R
and S-ifosfamide, metabolized through the CYP3A4 pathway.
Induction of CYP3A4 can increase activation of the drug and can
also generate more potentially neurotoxic metabolite (Wainer
et al., 1994; Antoniou and Tseng, 2005).
Anthracyclines (Daunorubicin and
Doxorubicin)
Anthracyclines are regularly used agents in the treatment of
both AIDS-related NHL and KS. Luckily, the potential for
DDIs between CYP-pathways and anthracyclines appears to be
minimum. Interactions with PIs or NNRTIs and CYP-pathways
may decrease reduction of free radicals, which may decrease both
antineoplastic and cytotoxic properties of the AC agents. Enzyme
inducers can do the opposite. Two pharmacokinetic analyses
were performed in HIV-patients with NHL treated with CHOP
with and without concurrent PI-based HAART (Vaccher et al.,
2001; Spina and Tirelli, 2004). The earliest study in 19 patients
showed that doxorubicin pharmacokinetics was not affected by
simultaneous PI administration, and PI exposures were not
altered by doxorubicin (Ratner et al., 2001).
Antimetabolites
They include several nucleoside analog drugs used in
combination with others antineoplastics in carcinomas and
NHLs. Luckily, the potential for adverse drug interactions with
HAART appears to be minimal, but the clinical trials in this field
are small.
Potential toxicity is considered for high exposures to etravirine
due to CYP2C9 inhibition. However, close monitoring should be
considered.
A cohort of 21 HIV-patients treated with HAART
(seven NRTI only, six on PI, six on NNRTI, and two on
PI/NNRTI-containing regimens) developed anal carcinoma and
received radiotherapy plus MMC and 5-FU without the need for
dose reductions. The CR rate was 81%, and 62% remained free
of any tumor relapse during additional follow-up (median, 53
months), without increased risk of HIV progression (Fraunholz
et al., 2010).
Case series of five HIV-positive patients on HAART (4 PI,
1 NRTI) with advanced colorectal cancer received oxaliplatin,
leucovorin and fluorouracil (FOLFOX-4 regimen) without
apparent increase in antineoplastic associated toxicity (Berretta
et al., 2008).
Miscellaneous
Camptothecins
Irinotecan (CPT-11), is a DNA topoisomerase I inhibitor
with a broad range of activity against solid tumors. The
model of (beta Fibrinogen Growth Factor) bFGF-induced
angiogenesis in mouse cornea suggested that Irinotecan
is also active in HIV-related KS (Martellotta et al., 2009).
Recent data show that lopinavir/ritonavir has a strong effect
on the pharmacokinetic profile of CPT-11 when used alone
in HIV patients with advanced KS (Corona et al., 2008).
Lopinavir/ritonavir reduces the clearance of CPT-11 by 47%;
the oxidized metabolite APC inhibited the formation of
SN38 glucuronide catabolite by 81%. This effect resulted in
increased availability of blood SN38 active metabolite with
consequent increased severe toxicity. Conversely, induction of
CYP3A4 or glucuronidation can decrease the effectiveness
of the drug (Corona et al., 2008). Pharmacogenomics
profile UGT1A1 ∗28 haplotype with homozygous 7 TA
repeat are high risk for irinotecan-related toxicities with
atazanavir, which also inhibits UGT1A1 (Corona et al.,
2008).
Tamoxifen
It is commonly used as an estrogens antagonist and undergoes
wide hepatic metabolism involving some isoforms of the
Cytochromes. Induction of CYP3A4 by tamoxifen may decrease
NNRTI or PI concentrations. Conversely, inhibition of CYP3A4
isoforms with PIs or NNRTIs can increase efficacy and both
risk and severity of tamoxifen-related adverse effects. Numerous
studies have shown that nelfinavir promotes in cancer cells,
autophagy and apoptosis cell cycle arrest, and may be a
valuable drug against breast cancer when combined with
tamoxifen in patients with hormone-responsive tumors (Brüning
et al., 2010). Interactions between HAART and aromatase
inhibitors are also hypothetically practicable (Liu et al., 2014).
Letrozole and exemestrane are both metabolized by CYP3A4
to inactive metabolites. NNRTIs may decrease the efficacy of
drugs conversely PIs may increase concentration and severity of
adverse effects of both letrozole and exemestrane (Buzdar et al.,
2002).
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Corticosteroids
Corticosteroids, are part of combination AC regimens
and may be subject to changes in their pharmacokinetic
and pharmacodynamic effects as a result of antiretroviral-
mediated modulation of their biotransformation. In particular
dexamethasone and methyl prednisolone are vulnerable to
interactions with HAART since the CYP3A4 isoform is the
primary enzyme mediating the metabolism of these drugs.
Dexamethasone may decrease concentrations of NNRTIs
and PIs. PIs may increase the pharmacodynamic effects of
corticosteroids when used concurrently. Conversely, CYP3A4
inducers may reduce the efficacy of these drugs. Therefore, it
is necessary to stop HAART in patients receiving prolonged
dexamethasone or alternatively consider the use of non-CYP3A4
inducing corticosteroid or antiretroviral drugs, with monitoring
if the combination is necessary (Antoniou and Tseng, 2005;
Mounier et al., 2009).
Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors account for a large panel of small
molecules that target tyrosine kinase protein domains of the wide
range species of growth factors receptors.
Erlotinib is approved for the treatment of non-small cell lung
(NSCLC) and pancreatic cancer. It is metabolized by CYP3A4.
Inducers or inhibitors of CYP3A4 enzymes such as PIs (e.g.,
ritonavir) or NNRTIs (e.g., efavirenz) can modify the metabolism
and efficacy of the drug. Recent data propose that to get the
desired drug exposure, the clinically used dose (150mg daily)
of Erlotinib must be significantly reduced (25mg every day) or
increase (300mg daily), respectively, when ritonavir or efavirenz
are co administered (Pillai et al., 2013).
Imatinib, a specific inhibitor of a tyrosine kinase associated
with the proto-oncogene c-kit, used in the treatment of chronic
myelogenous leukemia, is also metabolized by the CYP450
system.
Sunitinib, an oralmulti-targeted tyrosine kinase inhibitor used
for the treatment of advanced renal cancer and gastrointestinal
stromal tumors (GISTs) is biotransformed by CYP3A4 into
a most important pharmacologically active N-desmethyl
metabolite (Mounier et al., 2009). The inhibition of proteasomal
activity by specific proteasome inhibitors or cross-reactivity of
particular PIs with proteasomal enzymes recently became of
interest because of the anti-tumor properties of these molecules.
Bortezomib
Bortezomib used in association with nelfinavir, it induces cell
cycle arrest in cervical cancer cells as reflected by marked
changes in the expression of cell cycle regulatory cyclins and
ensuring mitochondrial independent apoptosis (Bruning et al.,
2001). Therefore, the combination with ritonavir inhibits renal
cancer growth synergistically at clinically feasible concentrations.
The effectiveness of the combination is caused by protein
ubiquitination and histone acetylation. In urological cancers,
Bortezomib was used in combination with Ritonavir with a
positive effect on protein ubiquitination (Bibas et al., 2010; Sato
et al., 2012).
Lenalidomide
Lenalidomide, is an analog of thalidomide that does not show
pharmacokinetic interaction with HAART because it is not
metabolized by the liver but is eliminated by the renal route
(Hertz et al., 2012).
CONCLUSION
As patients with HIV live longer, they developmoremalignancies
that are both HIV-related and unrelated. On this basis, a
better understanding of AC and HAART interactions is urgently
needed. DDIs are frequently encountered in the therapy of
cancer patients with HIV. All PIs are inhibitors of CYP3A,
which is central route in the metabolism of ∼50% of all AC
drugs. Among the PIs, ritonavir is the strongest inhibitor of
CYP3A activity. Conversely, NNRTIs can induce metabolism
and potentially reduce the efficacy of AC drugs. Even though
raltegravir has little potential for DDIs, the occurrence of viral
mutations limits its use as a single molecule. Interactions may
also be a consequence of a modification of the activities of
glucuronosyltransferase and/or of transport proteins. Ritonavir
is an inhibitor of P-glycoprotein, which leads to increased
exposure to many AC drugs. Generally, to prevent DDIs and
avoid severe toxicity, treatment options include substitution of
an antiretroviral alternative or temporary discontinuation of
HAART or selection of an alternative chemotherapy regimen.
Zidovudine is linked with severe neutropenia hence it should
not be combined with cytotoxic regimens containing neutropenic
agents. Didanosine and stavudine, old generation NRTIs, are
related with irreversible peripheral neuropathy which is also
a common side effect of platinating agents, taxanes, vinca
alkaloids, and bortezomib. AC-induced neuropathy is generally
cumulative or dose-related with management consisting of dose-
reduction or lower dose intensity. PIs and newer molecularly
targeted anti-cancer agents including the tyrosine kinase
inhibitors can cause QT prolongation, arrhythmias, and sudden
death. In addition, PIs appear to significantly potentiate the
myelotoxicity of AC. Bilirubin is often used as a marker for
dose adjustment for AC agents such as docetaxel, doxorubicin,
etoposide, irinotecan, paclitaxel, sorafenib, and vincristine.
Several antiretrovirals such as atazanavir and indinavir are
associated with unconjugated hyperbilirubinemia secondary to
UGT1A1 inhibition comparable to that which occurs in Gilbert’s
syndrome. If no other signs of liver dysfunction exist, suggested
dose modifications of AC based on liver function tests can be
ignored. Therefore, it is important that patients with cancer
should be screened for HIV infection, and treatment of HIV
infection should be started immediately. HAART should be
individualized according to the cancer treatment plan (AC or
radiotherapy or surgery), liver or renal diseases, bone marrow
suppression, mitochondrial dysfunction and individual patient
genotype.
Currently, drug interaction based on individual genomic
profile allows the prediction of the toxicity/inefficacy of
HAART/AC combined therapy (Table 2). It is well-known that
the response of taxane-based therapy is dependent on the
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individual’ CYP2C8∗3 allele and β-tubulin VI genotype profile
(Di Francia et al., 2013). The neurological effect of FOLFOX
therapy could be predicted by a pharmacogenomic panel test
performed before therapy (Lamba, 2009), as well as the lethal
effect of the DPYD risk genetic variant (Catapano et al., 2014).
In addition, therapy based on cytarabine and its related drug
Gemcitabine are affected by several polymorphisms found in the
Cytidine Deaminase (CDA) gene (Mitra et al., 2012; Kim et al.,
2013).
A change in the HAART regimen should be considered in the
case of overlapping toxic effects or DDIs between antiretroviral
drugs and AC or other drugs or to improve adherence and
tolerability.
We are now seeing that HIV treatment has entered into new
era in which multidrug treatments and genetic variations (host
and virus) must be taken into consideration when planning
chemotherapeutic/HAART regimens, in order to maximize
benefits and minimize toxicity (Gross et al., 2014).
Finally, a standard prophylaxis against OIs should be tailored
with drugs required for specific AC regimens.
In this scenario, the importance of cooperation between
oncologists and other health specialist (i.e., infectious disease,
pharmacogenetic, and lab specialist) must not be underestimated
in the management of these patients and design of an adequate
treatment strategy.
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